BioVector® MUG-Lucifer-prim 人骨肉瘤细胞系 / MUG-Lucifer-prim Human Osteosarcoma Cell Line

通用定义 / General Definition:BioVector® MUG-Lucifer-prim 是一种稳定表达萤火虫荧光素酶 (Firefly Luciferase) 的人源骨肉瘤 (Osteosarcoma) 细胞系。与高度转移性的 "met" 版本不同，"prim"（源自 Primary）版本代表的是模拟原发性肿瘤特征的细胞系。它由奥地利格拉茨医学院建立，通过整合报告基因，科研人员可以在非侵入性的情况下，利用生物发光成像技术 (BLI) 精确监测原位肿瘤的生长速率、容积变化以及早期定植情况。

BioVector® MUG-Lucifer-prim is a human Osteosarcoma cell line stably expressing the Firefly Luciferase reporter gene. Unlike the highly metastatic "met" variant, the "prim" (derived from Primary) version represents a cell line that mimics the characteristics of the primary tumor. Established by the Medical University of Graz, this line allows researchers to accurately monitor orthotopic tumor growth rates, volume changes, and early colonization in a non-invasive manner using Bioluminescence Imaging (BLI) technology.

BioVector® MUG-Lucifer-prim 技术说明书 (Technical Datasheet)

中文版说明书

1. 产品基本信息

• 产品名称： BioVector® MUG-Lucifer-prim 人骨肉瘤细胞

• 组织来源： 骨 (Bone)

• 标记基因： 萤火虫荧光素酶 (Firefly Luciferase)

• 生长特性： 贴壁生长

• 细胞形态： 成纤维细胞样、多角形

2. 培养条件

• 基础培养基： BioVector® RPMI-1640 与 DMEM (1:1) 混合培养基

• 血清添加： 10% BioVector® 优质胎牛血清 (FBS)

• 筛选/维持抗生素： 根据载体要求使用博来霉素 (Zeocin) 或 嘌呤霉素 (Puromycin)，以确保荧光素酶信号的长期稳定性。

• 培养环境： 37 摄氏度，5% CO2

• 传代比例： 1:3 至 1:5；建议在汇合度达到 80% 时进行传代。

3. 细胞应用

• 原位肿瘤模型： 构建小鼠原位骨肉瘤模型，监测原发灶的形成。

• 药效评估： 用于筛选抑制原发肿瘤生长的先导化合物。

• 生物发光示踪： 研究原发肿瘤微环境与其生长动力学之间的关系。

4. 注意事项

• 信号对比： 与 "met" 系列相比，"prim" 细胞通常用于观察局部肿瘤负荷。

• 底物处理： 活体实验前需使用 BioVector® 级 D-荧光素钠盐，并确保底物吸收时间一致以获得可重复的数据。

English Datasheet

1. General Product Information

• Product Name: BioVector® MUG-Lucifer-prim Human Osteosarcoma Cell Line

• Tissue Source: Bone

• Reporter Gene: Firefly Luciferase

• Growth Properties: Adherent

• Morphology: Fibroblast-like or polygonal

2. Culture Conditions

• Basal Medium: BioVector® RPMI-1640 and DMEM (1:1) mixture

• Serum Supplement: 10% BioVector® Fetal Bovine Serum (FBS)

• Selection/Maintenance: Supplement with appropriate Zeocin or Puromycin to prevent silencing of the Luciferase reporter.

• Incubation: 37 degrees Celsius, 5% CO2

• Subculturing: 1:3 to 1:5 ratio; subculture when cells reach 80% confluence.

3. Applications

• Orthotopic Tumor Models: Establishing localized bone tumor models in mice to monitor primary lesion formation.

• Drug Efficacy Screening: Assessing the effectiveness of lead compounds in suppressing the growth of the primary tumor mass.

• Bioluminescence Tracking: Investigating the correlation between the primary tumor microenvironment and growth kinetics.

4. Key Usage Notes

• Signal Comparison: While "met" cells are used for metastasis studies, the "prim" line is the preferred choice for studying localized tumor burden and primary expansion.

• Substrate Protocol: For in vivo imaging, use BioVector® grade D-Luciferin sodium salt. Ensure consistent substrate incubation times across experimental groups to guarantee reproducible quantification.

Note: To maintain the high luciferase activity of BioVector® MUG-Lucifer-prim, avoid long-term culture without selection pressure. Handle under Biosafety Level 2 (BSL-2) protocols. Periodic STR profiling is recommended for identity verification.

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

电话:400-800-2947

工作QQ/微信同号:1843439339

网址

http://www.biovector.net